Utidelone Treated for the Recurrent or Metastatic Urothelial Carcinoma
This study is a open-label, multicenter, phase II study to evaluate the efficacy and safety of utidelone in the recurrent or metastatic urothelial carcinoma after prior chemotherapy.
Metastatic Urothelial Carcinoma
DRUG: utidelone injection
Objective Response Rate, Reflected by percentage of tumor size reduction or regression, assessed by imaging techniques and expressed as Objective Response Rate (ORR）, 24 months
Clinical Benefit Rate, CR,PR and SD greater than or equal to 24 weeks, 24 weeks|Progression Free Survival (PFS), Time from date of administration of Utidelone to progression or death, 24 months|Adverse Events and Serious Adverse Events Safety, The incidence of grade ≥3 adverse reactions and the improvement of quality of life were observed, up to 3 years
This study is a open-label, multicenter, phase II study to evaluate the efficacy and safety of utidelone in the recurrent or metastatic urothelial carcinoma after prior chemotherapy.